Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 19;14:2861. doi: 10.1038/s41467-023-38581-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a, b Functional assays investigating the effect of pharmacological inhibition of SCD1 using a SCD1 specific inhibitor SSI4 in GX006 parental and 5FU + CDDP resistant organoid lines. Comparisons include DMSO versus 5FU + CDDP versus SSI4 versus combination of 5FU + CDDP and SSI4 (COMBO) using Annexin V-PI apoptosis (a) and in vitro limiting dilution spheroid formation assays (b). c Schematic diagram of treatment regimen comparing GX006 parental and 5FU + CDDP resistant organoid lines treated with DMSO or 5FU + CDDP and in combination with vehicle or SSI4. d, e Volume (d) and weight (e) of tumors derived from the indicated treatment groups at end point. f Waterfall plot showing the response of each tumor in each treatment group at end point. g Ex vivo limiting dilution assay of HCC tumors harvested from each treatment group to evaluate tumor-initiating cell frequency. (a) n = 4 independent experiments; (b) n = 3 independent experiments; (c–e) n = 8 mice. Significance were calculated by (a, d) two-way ANOVA; (b, g) one-sided extreme limiting dilution analysis; (e, f) one-way ANOVA. Data were presented as mean ± standard deviation. COMBO for combination. ns for not significant. Source data are provided as a Source Data file. Illustration for (c) was created using BioRender.com.